Business Wire

UK Co-ops Transform Retail With SymphonyAI’s AI-Powered Connected Retail Platform

3.9.2025 07:07:00 CEST | Business Wire | Press release

Share

AI-driven decision-making helps co-ops deliver better local assortments, reduce costs, and enhance member value

SymphonyAI, a leader in vertical AI solutions for enterprise transformation, today announced that Central Co-op, Lincolnshire, and Midcounties co-operatives have deployed its Connected Retail platform to modernise operations, localise assortments, and enhance the member experience across more than 700 stores serving over 1.3 million shoppers.

Amid rising operating costs, shifting consumer demand, and the need for hyper-local precision, the co-ops are using generative and predictive AI to make faster, more informed decisions. SymphonyAI’s platform delivers real-time intelligence across inventory management, shelf execution, and supply chain operations — driving efficiency, reducing waste, and creating more relevant store experiences.

“With SymphonyAI’s range and space planning, we can quickly adjust our assortments to meet changing member-shopper preferences while automating labour-intensive tasks to allow our teams to focus on delivering exceptional service,” said Jacob Isherwood, CIO, Midcounties Co-op.

“Our priority is to keep shelves stocked with the right products, reduce waste, and minimise overhead costs. With SymphonyAI’s platform, we’re able to enhance our operational efficiency and meet the evolving needs of our shoppers,” said Steve Leach, COO, Lincolnshire Co-op.

“As a member-owned business, our shoppers’ needs and preferences take top priority. With SymphonyAI’s connected retail platform, we have seamlessly integrated operations, ensuring shoppers are presented with the optimum range and high on-shelf availability,” said Selina Butterfield-Mashoofi, Chief Finance and Technology Officer, Central Co-operative.

Delivering Impact Through AI-Driven Retail

With SymphonyAI’s Connected Retail platform, the co-ops benefit from:

  • Localized Assortments tailored to community needs, reducing waste and driving loyalty
  • Smarter Shelf Execution with store-specific planograms and optimised space allocation
  • Operational Efficiency from predictive analytics and automated workflows that deliver value in weeks, not months

“The UK is a strategic growth market for us, and AI — especially generative AI — is at the heart of how we’re helping retailers unlock new value,” said Manish Choudhary, President, Symphony Retail CPG. “Our platform empowers real-time, intelligent decision-making that goes far beyond automation. It transforms complexity into opportunity — with measurable results for both retailers and shoppers.”

About Central Co-operative

Central Co-operative is one of the largest independent retail co-operative societies in the UK, with a heritage stretching back over 175 years. It has over 440 trading outlets, a family of around 7,700 colleagues, and more than 330,000 regular trading members.

About Lincolnshire Co-op

Lincolnshire Co-op is owned by its 300,000 members, the people of Lincolnshire and surrounding counties, and has been for more than 160 years. It runs 221 trading outlets, including 100 food stores.

About Midcounties Co-op

The Midcounties Co-operative is one of the UK’s largest independent consumer co-operative societies. It operates a range of businesses across Travel, Food Retail, Early Years, Utilities, Post Offices and Flexible Benefits. The society has over 750,000 members, employs over 6,000 colleagues and has an annual turnover of £1.5 billion.

With headquarters in Warwickshire, Midcounties Co-operative also has trading outlets across Oxfordshire, Gloucestershire, Wiltshire, Shropshire, West Midlands, Avon, Somerset, Dorset, Worcestershire, and the surrounding counties.

About SymphonyAI

SymphonyAI builds vertical AI applications that help enterprises tackle their most complex, high-value challenges—like stopping financial crime, improving store performance, and boosting manufacturing efficiency. Trusted by more than 2,000 enterprise customers in 26 countries, including 200 of the top financial institutions, top 25 CPGs, and many of the world’s largest grocers and industrial manufacturers. SymphonyAI delivers domain-trained applications and pre-built agents, ready to work on day one. Learn more at www.symphonyai.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250902131405/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye